866-997-4948(US-Canada Toll Free)

Womens Health Cluster Drug Development Pipeline Review, 2017

Published By :

GBI Research

Published Date : May 2017

Category :

Pharmaceutical

No. of Pages : 123 Pages

This report provides an overview of the women’s health pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for female infertility, polycystic ovarian syndrome and endometriosis, and also features dormant and discontinued projects.

The three key disorders covered in this report are largely driven by dysfunction of the endocrine system, but have a broad range of effects. Infertility is defined as the inability to get pregnant after a year of unprotected intercourse. Female infertility can be also be caused by a number of factors, which include damage to fallopian tubes, hormonal causes, cervical causes, uterine causes, unexplained infertility. Polycystic ovary syndrome (PCOS) is a common hormonal disorder among women of reproductive age. Symptoms include menstrual abnormality, acne, thinning hair on the scalp, weight gain, excess androgen and polycystic ovaries. Finally, endometriosis is an often painful disorder in which tissue that normally lines the inside of uterus (the endometrium) grows outside the uterus (endometrial implant). Symptoms include pelvic pain, menstrual cramps, inflammation, infertility and abnormal bleeding.

The size of these pipelines ranges from 12 in PCOS to 87 in female infertility. The most common types of therapy being developed in these diseases act on hormone receptors, reflecting the hormone-driven pathophysiology of this disease area. However, particularly in polycystic ovarian syndrome, a broader range of molecular targets, such as intracellular protein kinases, chemokine receptors and other cell signaling components are also targeted.

Scope

  • Which companies are the most active within the pipeline for women’s health therapeutics?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in the field of women’s health therapeutics?

Reasons to buy

  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Table of Contents

GBI Research Report Guidance 2

Executive Summary 3

Table of Contents 4
List of Tables 5
List of Figures 8

Introduction 9
Women's Health Cluster Report Coverage 9
Women Infertility – Overview 9
Polycystic Ovarian Syndrome – Overview 9
Endometriosis – Overview 9
Therapeutics Development 10
Women Infertility 10
Polycystic Ovarian Syndrome 18
Endometriosis 22
Therapeutics Assessment 29
Women Infertility 29
Polycystic Ovarian Syndrome 37
Endometriosis 45
Companies Involved in Therapeutics Development 53
Women Infertility 53
Polycystic Ovarian Syndrome 74
Endometriosis 77
Dormant Projects 89
Women Infertility 89
Polycystic Ovarian Syndrome 91
Endometriosis 92
Discontinued Products 93
Women Infertility 93
Polycystic Ovarian Syndrome 93
Endometriosis 94
Product Development Milestones 95
Women Infertility 95
Polycystic Ovarian Syndrome 105
Endometriosis 112

Appendix 122
Methodology 122
Coverage 122
Secondary Research 122
Primary Research 122
Expert Panel Validation 122
Contact Us 123
Disclaimer 123

List of Table

Number of Products under Development for Women Infertility 10
Number of Products under Development by Companies, Women Infertility 11
Number of Products under Development by Universities/Institutes, Women Infertility 13
Products under Development by Companies, Women Infertility 14
Products under Development by Universities/Institutes, Women Infertility 17
Number of Products under Development for Polycystic Ovarian Syndrome 18
Number of Products under Development by Companies, Polycystic Ovarian Syndrome 19
Number of Products under Development by Universities/Institutes, Polycystic Ovarian Syndrome 20
Products under Development by Companies, Polycystic Ovarian Syndrome 21
Products under Development by Universities/Institutes, Polycystic Ovarian Syndrome 21
Number of Products under Development for Endometriosis 22
Number of Products under Development by Companies, Endometriosis 24
Number of Products under Development by Universities/Institutes, Endometriosis 25
Products under Development by Companies, Endometriosis 26
Products under Development by Universities/Institutes, Endometriosis 28
Number of Products by Stage and Target, Women Infertility 30
Number of Products by Stage and Mechanism of Action, Women Infertility 32
Number of Products by Stage and Route of Administration, Women Infertility 34
Number of Products by Stage and Molecule Type, Women Infertility 36
Number of Products by Stage and Target, Polycystic Ovarian Syndrome 38
Number of Products by Stage and Mechanism of Action, Polycystic Ovarian Syndrome 40
Number of Products by Stage and Route of Administration, Polycystic Ovarian Syndrome 42
Number of Products by Stage and Molecule Type, Polycystic Ovarian Syndrome 44
Number of Products by Stage and Target, Endometriosis 46
Number of Products by Stage and Mechanism of Action, Endometriosis 48
Number of Products by Stage and Route of Administration, Endometriosis 50
Number of Products by Stage and Molecule Type, Endometriosis 52
Women Infertility – Pipeline by 4P Therapeutics LLC 53
Women Infertility – Pipeline by AbbVie Inc 53
Women Infertility – Pipeline by Addex Therapeutics Ltd 54
Women Infertility – Pipeline by AlphaMab Co Ltd 54
Women Infertility – Pipeline by APAvadis Biotechnologies Srl 55
Women Infertility – Pipeline by ASKA Pharmaceutical Co Ltd 55
Women Infertility – Pipeline by Astellas Pharma Inc 56
Women Infertility – Pipeline by Bayer AG 56
Women Infertility – Pipeline by Dong-A Socio Holdings Co Ltd 57
Women Infertility – Pipeline by Dongkook Pharmaceutical Co Ltd 57
Women Infertility – Pipeline by ElexoPharm GmbH 58
Women Infertility – Pipeline by EndoCeutics Inc 58
Women Infertility – Pipeline by Enteris BioPharma Inc 59
Women Infertility – Pipeline by Evotec AG 59
Women Infertility – Pipeline by Ferring International Center SA 60
Women Infertility – Pipeline by Forendo Pharma Ltd 60
Women Infertility – Pipeline by Glycotope GmbH 61
Women Infertility – Pipeline by Isifer AB 61
Women Infertility – Pipeline by Kissei Pharmaceutical Co Ltd 62
Women Infertility – Pipeline by Lipicard Technologies Ltd 62
Women Infertility – Pipeline by Livzon Pharmaceutical Group Inc 63
Women Infertility – Pipeline by Luye Pharma Group Ltd 63
Women Infertility – Pipeline by Merck & Co Inc 64
Women Infertility – Pipeline by Navya Biologicals Pvt Ltd 64
Women Infertility – Pipeline by Nippon Shinyaku Co Ltd 65
Women Infertility – Pipeline by Nora Therapeutics Inc 65
Women Infertility – Pipeline by ObsEva SA 66
Women Infertility – Pipeline by Ogeda SA 66
Women Infertility – Pipeline by Orphagen Pharmaceuticals Inc 67
Women Infertility – Pipeline by Pangen Biotech Inc. 67
Women Infertility – Pipeline by Pantec Biosolutions AG 68
Women Infertility – Pipeline by PharmaEssentia Corp 68
Women Infertility – Pipeline by Philogen SpA 69
Women Infertility – Pipeline by Repros Therapeutics Inc 69
Women Infertility – Pipeline by Richter Gedeon Nyrt 70
Women Infertility – Pipeline by SK Chemicals Co Ltd 70
Women Infertility – Pipeline by Takeda Pharmaceutical Company Ltd 71
Women Infertility – Pipeline by TocopheRx Inc 71
Women Infertility – Pipeline by ValiRx Plc 72
Women Infertility – Pipeline by Viramal Ltd 72
Women Infertility – Pipeline by Zydus Cadila Healthcare Ltd 73
Polycystic Ovarian Syndrome – Pipeline by Addex Therapeutics Ltd 74
Polycystic Ovarian Syndrome – Pipeline by Crinetics Pharmaceuticals Inc 74
Polycystic Ovarian Syndrome – Pipeline by EffRx Pharmaceuticals SA 75
Polycystic Ovarian Syndrome – Pipeline by Millendo Therapeutics Inc 75
Polycystic Ovarian Syndrome – Pipeline by Ogeda SA 76
Polycystic Ovarian Syndrome – Pipeline by Vicore Pharma AB 76
Endometriosis – Pipeline by AbbVie Inc 77
Endometriosis – Pipeline by Addex Therapeutics Ltd 77
Endometriosis – Pipeline by APAvadis Biotechnologies Srl 78
Endometriosis – Pipeline by Astellas Pharma Inc 78
Endometriosis – Pipeline by Bayer AG 79
Endometriosis – Pipeline by Dongkook Pharmaceutical Co Ltd 79
Endometriosis – Pipeline by ElexoPharm GmbH 80
Endometriosis – Pipeline by EndoCeutics Inc 80
Endometriosis – Pipeline by Enteris BioPharma Inc 81
Endometriosis – Pipeline by Evotec AG 81
Endometriosis – Pipeline by Forendo Pharma Ltd 82
Endometriosis – Pipeline by Kissei Pharmaceutical Co Ltd 82
Endometriosis – Pipeline by Lipicard Technologies Ltd 83
Endometriosis – Pipeline by Luye Pharma Group Ltd 83
Endometriosis – Pipeline by Nippon Shinyaku Co Ltd 84
Endometriosis – Pipeline by Ogeda SA 84
Endometriosis – Pipeline by Orphagen Pharmaceuticals Inc 85
Endometriosis – Pipeline by Philogen SpA 85
Endometriosis – Pipeline by Repros Therapeutics Inc 86
Endometriosis – Pipeline by SK Chemicals Co Ltd 86
Endometriosis – Pipeline by Takeda Pharmaceutical Company Ltd 87
Endometriosis – Pipeline by ValiRx Plc 87
Endometriosis – Pipeline by Viramal Ltd 88
Women Infertility – Dormant Projects 89
Polycystic Ovarian Syndrome – Dormant Projects 91
Endometriosis – Dormant Projects 92
Women Infertility – Discontinued Products 93
Polycystic Ovarian Syndrome – Discontinued Products 93
Endometriosis – Discontinued Products 94

List of Chart

Number of Products under Development for Women Infertility 10
Number of Products under Development by Companies, Women Infertility 11
Number of Products under Development by Universities/Institutes, Women Infertility 13
Number of Products under Development for Polycystic Ovarian Syndrome 18
Number of Products under Development by Companies, Polycystic Ovarian Syndrome 19
Number of Products under Development for Endometriosis 22
Number of Products under Development by Companies, Endometriosis 23
Number of Products under Development by Universities/Institutes, Endometriosis 25
Number of Products by Top 10 Targets, Women Infertility 29
Number of Products by Stage and Top 10 Targets, Women Infertility 29
Number of Products by Top 10 Mechanism of Actions, Women Infertility 31
Number of Products by Stage and Top 10 Mechanism of Actions, Women Infertility 31
Number of Products by Routes of Administration, Women Infertility 33
Number of Products by Stage and Routes of Administration, Women Infertility 33
Number of Products by Molecule Types, Women Infertility 35
Number of Products by Stage and Molecule Types, Women Infertility 35
Number of Products by Top 10 Targets, Polycystic Ovarian Syndrome 37
Number of Products by Stage and Top 10 Targets, Polycystic Ovarian Syndrome 37
Number of Products by Top 10 Mechanism of Actions, Polycystic Ovarian Syndrome 39
Number of Products by Stage and Top 10 Mechanism of Actions, Polycystic Ovarian Syndrome 39
Number of Products by Routes of Administration, Polycystic Ovarian Syndrome 41
Number of Products by Stage and Routes of Administration, Polycystic Ovarian Syndrome 41
Number of Products by Molecule Types, Polycystic Ovarian Syndrome 43
Number of Products by Stage and Molecule Types, Polycystic Ovarian Syndrome 43
Number of Products by Top 10 Targets, Endometriosis 45
Number of Products by Stage and Top 10 Targets, Endometriosis 45
Number of Products by Top 10 Mechanism of Actions, Endometriosis 47
Number of Products by Stage and Top 10 Mechanism of Actions, Endometriosis 47
Number of Products by Routes of Administration, Endometriosis 49
Number of Products by Stage and Routes of Administration, Endometriosis 49
Number of Products by Molecule Types, Endometriosis 51
Number of Products by Stage and Molecule Types, Endometriosis 51

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *